Unraveling the glioma epigenome-from molecular mechanisms to novel biomarkers and therapeutic targets

Brain Pathology

Volumn 21, Issue 6, 2011, Pages 619-632

  Malzkorn, Bastian ^a   Wolter, Marietta ^a   Riemenschneider, Markus J ^b   Reifenberger, Guido ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

DNA methylation; glioma; histone modification; IDH1; MGMT

Indexed keywords

2 HYDROXYGLUTARIC ACID; 2 OXOGLUTARIC ACID; 5 METHYLCYTOSINE; BIOLOGICAL MARKER; HISTONE DEMETHYLASE; ISOCITRATE DEHYDROGENASE;

CPG ISLAND; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; GENE EXPRESSION REGULATION; GENE MUTATION; GENE SEQUENCE; GENE SILENCING; GENE TRANSLOCATION; GENOMIC INSTABILITY; GLIOMA; HISTONE MODIFICATION; HUMAN; MOLECULAR MECHANICS; NONHUMAN; PROMOTER REGION; REVIEW;

ANIMALS; BRAIN NEOPLASMS; EPIGENESIS, GENETIC; GLIOMA; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 80054708001     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2011.00536.x     Document Type: Review

References (154)

1. Alaminos M, Dávalos V, Ropero S, Setién F, Paz MF, Herranz M, et al, (2005) EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. Cancer Res 65: 2565-2571. (Pubitemid 40490052)
2. Alonso ME, Bello MJ, Gonzalez-Gomez P, Arjona D, Lomas J, de Campos JM, et al, (2003) Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas. Cancer Genet Cytogenet 144: 134-142. (Pubitemid 36808960)
3. Andrews AJ, Luger K, (2011) Nucleosome structure(s) and stability: variations on a theme. Annu Rev Biophys 40: 99-117.
4. Aravin AA, Sachidanandam R, Bourc'his D, Schaefer C, Pezic D, Toth KF, et al, (2008) A piRNA pathway primed by individual transposons is linked to de novo DNA methylation in mice. Mol Cell 31: 785-799.
5. Avvakumov N, Nourani A, Côté J, (2011) Histone chaperones: modulators of chromatin marks. Mol Cell 41: 502-514.
6. Baeza N, Weller M, Yonekawa Y, Kleihues P, Ohgaki H, (2003) PTEN methylation and expression in glioblastomas. Acta Neuropathol 106: 479-485. (Pubitemid 37265852)
7. Balaña C, Ramirez JL, Taron M, Roussos Y, Ariza A, Ballester R, et al, (2003) O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 9: 1461-1468. (Pubitemid 36418402)
8. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A, (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116: 597-602.
9. Bannister AJ, Kouzarides T, (2011) Regulation of chromatin by histone modifications. Cell Res 21: 381-395.
10. Barski A, Cuddapah S, Cui K, Roh T, Schones DE, Wang Z, et al, (2007) High-resolution profiling of histone methylations in the human genome. Cell 129: 823-837. (Pubitemid 46802390)
11. Berdasco M, Ropero S, Setien F, Fraga MF, Lapunzina P, Losson R, et al, (2009) Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma. Proc Natl Acad Sci USA 106: 21830-21835.
12. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A, (2009) An operational definition of epigenetics. Genes Dev 23: 781-783.
13. Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, et al, (2011) Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333: 1453-1455.
14. Bettstetter M, Dechant S, Ruemmele P, Vogel C, Kurz K, Morak M, et al, (2008) MethyQESD, a robust and fast method for quantitative methylation analyses in HNPCC diagnostics using formalin-fixed and paraffin-embedded tissue samples. Lab Invest 88: 1367-1375.
15. Blasco MA, (2007) The epigenetic regulation of mammalian telomeres. Nat Rev Genet 8: 299-309. (Pubitemid 46439289)
16. Boumber Y, Issa JJ, (2011) Epigenetics in cancer: what's the future? Oncology (Williston Park) 25: 220-226. 228.
17. Cadieux B, Ching T, Vandenberg SR, Costello JF, (2006) Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. Cancer Res 66: 8469-8476. (Pubitemid 44449159)
18. Campos B, Bermejo JL, Han L, Felsberg J, Ahmadi R, Grabe N, et al, (2011) Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas. Cancer Sci 102: 387-392.
19. Chen Z, Riggs AD, (2011) DNA methylation and demethylation in mammals. J Biol Chem 286: 18347-18353.
20. Christensen BC, Smith AA, Zheng S, Koestler DC, Houseman EA, Marsit CJ, et al, (2011) DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst 103: 143-153.
21. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R, (2003) Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. BioTechniques 35: 146-150. (Pubitemid 36828724)
22. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, et al, (2010) A multigene predictor of outcome in glioblastoma. Neuro-Oncol 12: 49-57.
23. Corpet A, Koning L, Toedling J, Savignoni A, Berger F, Lemaître C, et al, (2011) Asf1b, the necessary Asf1 isoform for proliferation, is predictive of outcome in breast cancer. EMBO J 30: 480-493.
24. Costa BM, Smith JS, Chen Y, Chen J, Phillips HS, Aldape KD, et al, (2010) Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Res 70: 453-462.
25. Costello JF, Berger MS, Huang HS, Cavenee WK, (1996) Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 56: 2405-2410. (Pubitemid 26154090)
26. Dahl C, Grànbäk K, Guldberg P, (2011) Advances in DNA methylation: 5-hydroxymethylcytosine revisited. Clin Chim Acta 412: 831-836.
27. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al, (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462: 739-744.
28. Doi A, Park I, Wen B, Murakami P, Aryee MJ, Irizarry R, et al, (2009) Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 41: 1350-1353.
29. Dou Y, Milne TA, Tackett AJ, Smith ER, Fukuda A, Wysocka J, et al, (2005) Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell 121: 873-885. (Pubitemid 40806419)
30. D'Urso PI, D'Urso OF, Storelli C, Catapano G, Gianfreda CD, Montinaro A, et al, (2010) Retrospective protein expression and epigenetic inactivation studies of CDH1 in patients affected by low-grade glioma. J Neurooncol 104: 113-118.
31. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, et al, (2000) MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28: E32.
32. Eden A, Gaudet F, Waghmare A, Jaenisch R, (2003) Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300: 455. (Pubitemid 36444319)
33. Entin-Meer M, Yang X, Vandenberg SR, Lamborn KR, Nudelman A, Rephaeli A, et al, (2007) In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Neuro-Oncol 9: 82-88. (Pubitemid 46580309)
34. Esteller M, (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8: 286-298. (Pubitemid 46439286)
35. Esteller M, Corn PG, Baylin SB, Herman JG, (2001) A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229. (Pubitemid 32695003)
36. Eyüpoglu IY, Hahnen E, Buslei R, Siebzehnrübl FA, Savaskan NE, Lüders M, et al, (2005) Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. J Neurochem 93: 992-999. (Pubitemid 40695758)
37. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al, (2007) MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 104: 15805-15810. (Pubitemid 350035380)
38. Fathi AT, Abdel-Wahab O, (2012) Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy, Advances in Hematology [Epub ahead of print; doi:10.1155/2012/469592].
39. Feinberg AP, (2005) Cancer epigenetics is no Mickey Mouse. Cancer Cell 8: 267-268. (Pubitemid 41443410)
40. Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M, et al, (2011) Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer 129: 659-670.
41. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al, (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18: 553-567.
42. Fouse SD, Nagarajan RP, Costello JF, (2010) Genome-scale DNA methylation analysis. Epigenomics 2: 105-117.
43. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, et al, (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37: 391-400.
44. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, et al, (1992) A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 89: 1827-1831.
45. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, et al, (2009) Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 27: 2052-2058.
46. Gerson SL, (2004) MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4: 296-307. (Pubitemid 38525285)
47. Godlewski J, Nowicki MO, Bronisz A, Williams S, Otsuki A, Nuovo G, et al, (2008) Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res 68: 9125-9130.
48. Götze S, Feldhaus V, Traska T, Wolter M, Reifenberger G, Tannapfel A, et al, (2009) ECRG4 is a candidate tumor suppressor gene frequently hypermethylated in colorectal carcinoma and glioma. BMC Cancer 9: 447.
49. Götze S, Wolter M, Reifenberger G, Müller O, Sievers S, (2010) Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas. Int J Cancer 126: 2584-2593.
50. Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, et al, (2011) Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 43: 875-878.
51. Hasselblatt M, Gesk S, Oyen F, Rossi S, Viscardi E, Giangaspero F, et al, (2011) Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression. Am J Surg Pathol 35: 933-935.
52. Hayashizaki Y, Hirotsune S, Okazaki Y, Hatada I, Shibata H, Kawai J, et al, (1993) Restriction landmark genomic scanning method and its various applications. Electrophoresis 14: 251-258. (Pubitemid 23147986)
53. He Y, Li B, Li Z, Liu P, Wang Y, Tang Q, et al, (2011) Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333: 1303-1307.
54. Hegi ME, Diserens A, Gorlia T, Hamou M, de Tribolet N, Weller M, et al, (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003. (Pubitemid 40349502)
55. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB, (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826. (Pubitemid 26296693)
56. Horiguchi K, Tomizawa Y, Tosaka M, Ishiuchi S, Kurihara H, Mori M, et al, (2003) Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors. Oncogene 22: 7862-7865. (Pubitemid 37485546)
57. Huang TH, Perry MR, Laux DE, (1999) Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet 8: 459-470. (Pubitemid 29097334)
58. Iguchi-Ariga SM, Schaffner W, (1989) CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. Genes Dev 3: 612-619.
59. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, et al, (2009) The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 41: 178-186.
60. Issa J, (2004) CpG island methylator phenotype in cancer. Nat Rev Cancer 4: 988-993. (Pubitemid 39626222)
61. Jeuken JWM, Cornelissen SJB, Vriezen M, Dekkers MMG, Errami A, Sijben A, et al, (2007) MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 87: 1055-1065. (Pubitemid 47429190)
62. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, et al, (2011) DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331: 1199-1203.
63. Jin S, Kadam S, Pfeifer GP, (2010) Examination of the specificity of DNA methylation profiling techniques towards 5-methylcytosine and 5-hydroxymethylcytosine. Nucleic Acids Res 38: e125.
64. Kalantry S, (2011) Recent advances in X-chromosome inactivation. J Cell Physiol 226: 1714-1718.
65. Kapoor A, Goldberg MS, Cumberland LK, Ratnakumar K, Segura MF, Emanuel PO, et al, (2010) The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature 468: 1105-1109.
66. Kim DH, Saetrom P, Snàve O, Rossi JJ, (2008) MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci USA 105: 16230-16235.
67. Kim Y, Pierscianek D, Mittelbronn M, Vital A, Mariani L, Hasselblatt M, et al, (2011) TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations. J Clin Pathol 64: 850-852.
68. Knobbe CB, Reifenberger J, Blaschke B, Reifenberger G, (2004) Hypermethylation and transcriptional downregulation of the carboxyl-terminal modulator protein gene in glioblastomas. J Natl Cancer Inst 96: 483-486. (Pubitemid 38443652)
69. Korber P, Becker PB, (2010) Nucleosome dynamics and epigenetic stability. Essays Biochem 48: 63-74.
70. Kriaucionis S, Heintz N, (2009) The nuclear DNA base 5- hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 324: 929-930.
71. Kulis M, Esteller M, (2010) DNA methylation and cancer. Adv Genet 70: 27-56.
72. Kunej T, Godnic I, Ferdin J, Horvat S, Dovc P, Calin GA, (2011) Epigenetic regulation of microRNAs in cancer: an integrated review of literature. Mutat Res [Epub ahead of print].
73. Kunitz A, Wolter M, van den Boom J, Felsberg J, Tews B, Hahn M, et al, (2007) DNA hypermethylation and aberrant expression of the EMP3 gene at 19q13.3 in Human Gliomas. Brain Pathol 17: 363-370. (Pubitemid 47537593)
74. Laffaire J, Everhard S, Idbaih A, Crinière E, Marie Y, Reyniès A, et al, (2011) Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro-Oncol 13: 84-98.
75. Lavon I, Refael M, Zelikovitch B, Shalom E, Siegal T, (2010) Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro-Oncol 12: 173-180.
76. Lehnertz B, Ueda Y, Derijck AAHA, Braunschweig U, Perez-Burgos L, Kubicek S, et al, (2003) Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin. Curr Biol 13: 1192-1200. (Pubitemid 36872941)
77. Li Y, Sasaki H, (2011) Genomic imprinting in mammals: its life cycle, molecular mechanisms and reprogramming. Cell Res 21: 466-473.
78. Li B, Carey M, Workman JL, (2007) The role of chromatin during transcription. Cell 128: 707-719. (Pubitemid 46273570)
79. Lindemann C, Hackmann O, Delic S, Schmidt N, Reifenberger G, Riemenschneider MJ, (2011) SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation. Acta Neuropathol 122 (2): 241-251.
80. Liu B, Cheng J, Zhang X, Wang R, Zhang W, Lin H, et al, (2010) Global histone modification patterns as prognostic markers to classify glioma patients. Cancer Epidemiol Biomarkers Prev 19: 2888-2896.
81. Liu B, Cheng J, Zhang W, Zhang X, Wang R, Lin H, et al, (2010) Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas. Neuro-Oncol 12: 540-548.
82. Lo WS, Duggan L, Emre NC, Belotserkovskya R, Lane WS, Shiekhattar R, et al, (2001) Snf1-a histone kinase that works in concert with the histone acetyltransferase Gcn5 to regulate transcription. Science 293: 1142-1146. (Pubitemid 32758096)
83. Lorente A, Mueller W, Urdangarín E, Lázcoz P, Lass U, von Deimling A, et al, (2009) RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs. Brain Pathol 19: 279-292.
84. Lucio-Eterovic AKB, Cortez MAA, Valera ET, Motta FJN, Queiroz RGP, Machado HR, et al, (2008) Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer 8: 243.
85. Luco RF, Allo M, Schor IE, Kornblihtt AR, Misteli T, (2011) Epigenetics in alternative pre-mRNA splicing. Cell 144: 16-26.
86. Martinez R, Esteller M, (2010) The DNA methylome of glioblastoma multiforme. Neurobiol Dis 39: 40-46.
87. Martinowich K, Hattori D, Wu H, Fouse S, He F, Hu Y, et al, (2003) DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 302: 890-893. (Pubitemid 37339633)
88. Masoudi A, Elopre M, Amini E, Nagel ME, Ater JL, Gopalakrishnan V, et al, (2008) Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res 28: 2437-2442.
89. Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, Sivachenko A, et al, (2008) Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454: 766-770.
90. Meluh PB, Koshland D, (1997) Budding yeast centromere composition and assembly as revealed by in vivo cross-linking. Genes Dev 11: 3401-3412. (Pubitemid 28023962)
91. Mikeska T, Bock C, El-Maarri O, Hübner A, Ehrentraut D, Schramm J, et al, (2007) Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn 9: 368-381. (Pubitemid 47305073)
92. Mohn F, Weber M, Rebhan M, Roloff TC, Richter J, Stadler MB, et al, (2008) Lineage-specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors. Mol Cell 30: 755-766.
93. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, et al, (2011) Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476: 298-303.
94. Mottet D, Pirotte S, Lamour V, Hagedorn M, Javerzat S, Bikfalvi A, et al, (2009) HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene 28: 243-256.
95. Murr R, (2010) Interplay between different epigenetic modifications and mechanisms. Adv Genet 70: 101-141.
96. Nakamura M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H, (2001) Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C-A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 22: 1715-1719. (Pubitemid 32952152)
97. Nakamura M, Watanabe T, Klangby U, Asker C, Wiman K, Yonekawa Y, et al, (2001) p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 11: 159-168. (Pubitemid 32198843)
98. Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H, (2001) Promoter hypermethylation of the RB1 gene in glioblastomas. Lab Invest 81: 77-82. (Pubitemid 32108641)
99. Nakamura M, Ishida E, Shimada K, Kishi M, Nakase H, Sakaki T, et al, (2005) Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas. Lab Invest 85: 165-175. (Pubitemid 40208920)
100. Nakayama J, Rice JC, Strahl BD, Allis CD, Grewal SI, (2001) Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science 292: 110-113. (Pubitemid 32289138)
101. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al, (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522.
102. Nygren AOH, Ameziane N, Duarte HMB, Vijzelaar RNCP, Waisfisz Q, Hess CJ, et al, (2005) Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res 33: e128.
103. Ohka F, Natsume A, Motomura K, Kishida Y, Kondo Y, Abe T, et al, (2011) The Global DNA Methylation Surrogate LINE-1 Methylation Is Correlated with MGMT Promoter Methylation and Is a Better Prognostic Factor for Glioma. PLoS ONE 6: e23332.
104. Ooi SKT, Qiu C, Bernstein E, Li K, Jia D, Yang Z, et al, (2007) DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 448: 714-717. (Pubitemid 47236857)
105. Papait R, Magrassi L, Rigamonti D, Cattaneo E, (2009) Temozolomide and carmustine cause large-scale heterochromatin reorganization in glioma cells. Biochem Biophys Res Commun 379: 434-439.
106. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al, (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
107. Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, et al, (2011) The genetic landscape of the childhood cancer medulloblastoma. Science 331: 435-439.
108. Rajendran G, Shanmuganandam K, Bendre A, Mujumdar D, Goel A, Shiras A, (2011) Epigenetic regulation of DNA methyltransferases: DNMT1 and DNMT3B in gliomas. J Neurooncol 104: 483-494.
109. Rauch T, Pfeifer GP, (2005) Methylated-CpG island recovery assay: a new technique for the rapid detection of methylated-CpG islands in cancer. Lab Invest 85: 1172-1180. (Pubitemid 43073989)
110. Rea S, Eisenhaber F, O'Carroll D, Strahl BD, Sun ZW, Schmid M, et al, (2000) Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 406: 593-599. (Pubitemid 30641039)
111. Reitman ZJ, Yan H, (2010) Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 102: 932-941.
112. Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, et al, (2011) Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci USA 108: 3270-3275.
113. Ren B, Robert F, Wyrick JJ, Aparicio O, Jennings EG, Simon I, et al, (2000) Genome-wide location and function of DNA binding proteins. Science 290: 2306-2309. (Pubitemid 32041573)
114. Riemenschneider MJ, Reifenberger J, Reifenberger G, (2008) Frequent biallelic inactivation and transcriptional silencing of the DIRAS3 gene at 1p31 in oligodendroglial tumors with 1p loss. Int J Cancer 122: 2503-2510. (Pubitemid 351590483)
115. Riemenschneider MJ, Jeuken JWM, Wesseling P, Reifenberger G, (2010) Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 120: 567-584.
116. Riemenschneider MJ, Hegi ME, Reifenberger G, (2010) MGMT promoter methylation in malignant gliomas. Target Oncol 5: 161-165.
117. Rodríguez-Paredes M, Esteller M, (2011) Cancer epigenetics reaches mainstream oncology. Nat Med 17: 330-339.
118. Rottach A, Frauer C, Pichler G, Bonapace IM, Spada F, Leonhardt H, (2010) The multi-domain protein Np95 connects DNA methylation and histone modification. Nucleic Acids Res 38: 1796-1804.
119. Schmidt N, Windmann S, Reifenberger G, Riemenschneider MJ, (2011) DNA hypermethylation and histone modifications downregulate the candidate tumor suppressor gene RRP22 on 22q12 in human gliomas. Brain pathology (Zurich, Switzerland).
120. Stimpson KM, Sullivan BA, (2010) Epigenomics of centromere assembly and function. Curr Opin Cell Biol 22: 772-780.
121. Stone AR, Bobo W, Brat DJ, Devi NS, van Meir EG, Vertino PM, (2004) Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. Am J Pathol 165: 1151-1161. (Pubitemid 39297722)
122. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al, (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. (Pubitemid 40349501)
123. Suzuki MM, Bird A, (2008) DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 9: 465-476. (Pubitemid 351693975)
124. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al, (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324: 930-935.
125. Talbert PB, Henikoff S, (2010) Histone variants-ancient wrap artists of the epigenome. Nat Rev Mol Cell Biol 11: 264-275.
126. Tepel M, Roerig P, Wolter M, Gutmann DH, Perry A, Reifenberger G, et al, (2008) Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int J Cancer 123: 2080-2086.
127. Tews B, Roerig P, Hartmann C, Hahn M, Felsberg J, Blaschke B, et al, (2007) Hypermethylation and transcriptional downregulation of the CITED4 gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19q. Oncogene 26: 5010-5016. (Pubitemid 47172644)
128. Tost J, Dunker J, Gut IG, (2003) Analysis and quantification of multiple methylation variable positions in CpG islands by Pyrosequencing. BioTechniques 35: 152-156. (Pubitemid 36828725)
129. Toyota M, Ho C, Ahuja N, Jair KW, Li Q, Ohe-Toyota M, et al, (1999) Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 59: 2307-2312. (Pubitemid 29242273)
130. Tsai W, Wang Z, Yiu TT, Akdemir KC, Xia W, Winter S, et al, (2010) TRIM24 links a non-canonical histone signature to breast cancer. Nature 468: 927-932.
131. Uhlmann K, Rohde K, Zeller C, Szymas J, Vogel S, Marczinek K, et al, (2003) Distinct methylation profiles of glioma subtypes. Int J Cancer 106: 52-59. (Pubitemid 36750387)
132. Unoki M, Nishidate T, Nakamura Y, (2004) ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene 23: 7601-7610. (Pubitemid 39424918)
133. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJB, Wesseling P, et al, (2010) IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 16: 1597-1604.
134. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, et al, (2011) Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469: 539-542.
135. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al, (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
136. Wade PA, (2001) Methyl CpG binding proteins: coupling chromatin architecture to gene regulation. Oncogene 20: 3166-3173. (Pubitemid 32553572)
137. Waha A, Güntner S, Huang TH, Yan PS, Arslan B, Pietsch T, et al, (2005) Epigenetic silencing of the protocadherin family member PCDH-gamma-A11 in astrocytomas. Neoplasia 7: 193-199. (Pubitemid 40411631)
138. Wang Y, Leung FCC, (2004) An evaluation of new criteria for CpG islands in the human genome as gene markers. Bioinformatics 20: 1170-1177. (Pubitemid 38660354)
139. Wang H, Wang S, Shen L, Chen Y, Zhang X, Zhou J, et al, (2010) Chk2 down-regulation by promoter hypermethylation in human bulk gliomas. Life Sci 86: 185-191.
140. Watt PM, Kumar R, Kees UR, (2000) Promoter demethylation accompanies reactivation of the HOX11 proto-oncogene in leukemia. Genes Chromosomes Cancer 29: 371-377.
141. Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, Lam WL, et al, (2005) Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 37: 853-862. (Pubitemid 41077111)
142. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, et al, (2010) MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6: 39-51.
143. Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, et al, (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 77: 1156-1164.
144. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al, (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27: 5874-5880.
145. Wilson BG, Roberts CWM, (2011) SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 11: 481-492.
146. Wolter M, Reifenberger J, Blaschke B, Ichimura K, Schmidt EE, Collins VP, et al, (2001) Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes. J Neuropathol Exp Neurol 60: 1170-1180. (Pubitemid 33117097)
147. Wu SC, Zhang Y, (2010) Active DNA demethylation: many roads lead to Rome. Nat Rev Mol Cell Biol 11: 607-620.
148. Xiong Z, Laird PW, (1997) COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 25: 2532-2534. (Pubitemid 27303718)
149. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim S, et al, (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19: 17-30.
150. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al, (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773.
151. Yin D, Ong JM, Hu J, Desmond JC, Kawamata N, Konda BM, et al, (2007) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res 13: 1045-1052. (Pubitemid 46340384)
152. Yun M, Wu J, Workman JL, Li B, (2011) Readers of histone modifications. Cell Res 21: 564-578.
153. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, et al, (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324: 261-265.
154. Zhou H, Hu H, Lai M, (2010) Non-coding RNAs and their epigenetic regulatory mechanisms. Biol Cell 102: 645-655.